Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update
09 août 2017 07h00 HE
|
Protalix BioTherapeutics, Inc.
Cystic Fibrosis Foundation Approves Letter of Application Enabling Protalix to Apply for Grant Funding Debt Refinancing and Financing Significantly improves Financial Position CARMIEL, Israel, Aug. ...
Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017
31 juil. 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, July 31, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
25 juil. 2017 16h27 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, July 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (“Protalix” or the “Company”) announced today the entry into a definitive exchange...
Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference
07 juin 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
New clinical data reported on ppFEV1 measurement taken after washout of alidornase alfa demonstrates meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further...
Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
01 juin 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, June 01, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that a Supplemental New Drug Application (sNDA) submitted to the U.S....
Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference
25 mai 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
23 mai 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 23, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the...
Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
10 mai 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next...
Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease
09 mai 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
Once Monthly Dosing Would Represent a 50% Reduction in Patient Infusions Unique Chemical Modifications to pegunigalsidase alfa Result in a Significantly Longer Half-life Allowing for the Potential of...
Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017
01 mai 2017 07h49 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 01, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...